Stockscreener 앱 받기
43.65
1.93%
0.72
전일 마감가:
$42.93
열려 있는:
$45.07
하루 거래량:
199.40K
Relative Volume:
0.43
시가총액:
$2.94B
수익:
$35.93M
순이익/손실:
$-244.56M
주가수익비율:
-11.61
EPS:
-3.76
순현금흐름:
$-157.31M
1주 성능:
-11.88%
1개월 성능:
-15.20%
6개월 성능:
+0.09%
1년 성능:
+84.95%
1일 변동 폭
$43.20
$45.76
1주일 범위
$42.30
$50.98
52주 변동 폭
$22.26
$61.61
Merus N V Stock (MRUS) Company Profile
명칭
Merus N V
전화
31 030 253 8800
주소
YALELAAN 62, 3584 CM UTRECHT
MRUS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| MRUS | 43.62 | 2.94B | 35.93M | -244.56M | -157.31M | -3.76 |
| VRTX | 447.00 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 739.78 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.30 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.57 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.41 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-02 | 개시 | Canaccord Genuity | Buy |
| 2023-08-21 | 개시 | TD Cowen | Outperform |
| 2022-08-02 | 개시 | Stifel | Buy |
| 2022-02-11 | 개시 | BMO Capital Markets | Outperform |
| 2022-02-10 | 개시 | Needham | Buy |
| 2021-11-17 | 재개 | Guggenheim | Buy |
| 2021-06-07 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-04-08 | 개시 | William Blair | Outperform |
| 2021-03-16 | 개시 | SVB Leerink | Outperform |
| 2020-06-26 | 개시 | H.C. Wainwright | Buy |
| 2020-05-27 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-20 | 재개 | Guggenheim | Buy |
| 2019-06-28 | 개시 | ROTH Capital | Buy |
| 2019-04-12 | 재개 | Guggenheim | Buy |
| 2019-04-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-03-27 | 개시 | Berenberg | Buy |
| 2018-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-03-21 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-12-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2016-11-07 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-06-13 | 개시 | Citigroup | Buy |
| 2016-06-13 | 개시 | Guggenheim | Buy |
| 2016-06-13 | 개시 | Wedbush | Outperform |
모두보기
Merus N V 주식(MRUS)의 최신 뉴스
The Goldman Sachs Group Initiates Coverage on Merus (NASDAQ:MRUS) - MarketBeat
Merus initiated with a Buy at Goldman Sachs - TipRanks
Needham & Company LLC Reaffirms Buy Rating for Merus (NASDAQ:MRUS) - MarketBeat
Merus (NASDAQ:MRUS) Shares Sold by First Turn Management LLC - MarketBeat
37,426 Shares in Merus (NASDAQ:MRUS) Acquired by State of New Jersey Common Pension Fund D - Defense World
Merus is Now Oversold (MRUS) - Nasdaq
GSA Capital Partners LLP Purchases Shares of 13,502 Merus (NASDAQ:MRUS) - MarketBeat
2,054 Shares in Merus (NASDAQ:MRUS) Purchased by US Bancorp DE - Defense World
Commodore Capital LP Bolsters Stake in Merus NV - GuruFocus.com
SAMLYN CAPITAL, LLC Bolsters Stake in Merus NV - GuruFocus.com
(MRUS) Trading Report - Stock Traders Daily
Is Merus N.V. (MRUS) Top Performing European Stock Heading into 2025? - MSN
FMR LLC Bolsters Stake in Merus NV - GuruFocus.com
10 Top Performing European Stocks Heading into 2025 - Insider Monkey
Merus (NASDAQ:MRUS) Shares Bought by TimesSquare Capital Management LLC - MarketBeat
US FDA extends review of Merus' gene-targeting cancer therapy - MSN
Merus (NASDAQ:MRUS) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Merus (NASDAQ:MRUS) Receives $86.70 Consensus Price Target from Brokerages - MarketBeat
MRUSMerus N.V. Common Shares Latest Stock News & Market Updates - StockTitan
Merus to Present at Upcoming Investor Conferences - The Manila Times
Merus Receives FDA extension of PDUFA for zenocutuzumab - GlobeNewswire
FDA extends review date for Merus' cancer drug Zeno By Investing.com - Investing.com Canada
FDA extends review date for Merus' cancer drug Zeno - Investing.com India
Merus (NASDAQ:MRUS) Shares Gap DownHere's Why - MarketBeat
Merus: Petosemtamab Set Up For December 2024 Data Presentation (NASDAQ:MRUS) - Seeking Alpha
FDA extends review period for Merus's cancer drug Zeno - Investing.com India
Merus : FDA Extends Review of Cancer Drug Zenocutuzumab to February - Marketscreener.com
US FDA extends review of Merus’ gene-targeting cancer therapy - PharmaLive
Merus says FDA extended review period for cancer drug - MSN
Merus stock slips as FDA delays drug review (MRUS:NASDAQ) - Seeking Alpha
FDA extends review period for Merus's cancer drug Zeno By Investing.com - Investing.com Canada
Harbor Capital Advisors Inc. Buys New Holdings in Merus (NASDAQ:MRUS) - MarketBeat
abrdn plc Invests $4.36 Million in Merus (NASDAQ:MRUS) - MarketBeat
Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Merus sees cash runway into 2028 - MSN
Merus reports Q3 EPS ($1.46), consensus (88c) - MSN
Merus annonce ses résultats financiers pour le troisième trimestre 2024 et fait le point sur ses activités - GlobeNewswire Inc.
Merus (NASDAQ:MRUS) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Merus N.V. Reports Q3 2024 Financial Results - TipRanks
Merus falls after updated data for lung cancer therapy - MSN
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update - GlobeNewswire
Novo Holdings A S Increases Position in Merus (NASDAQ:MRUS) - MarketBeat
Merus (NASDAQ:MRUS) Coverage Initiated at UBS Group - Defense World
UBS sees upside in Merus stock, highlights potential in head and neck cancer treatment - Investing.com India
Merus N V (MRUS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Merus N V 주식 (MRUS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Shuman Harry | VP Controller, PAO |
Aug 20 '24 |
Sale |
54.00 |
2,500 |
135,000 |
7,002 |
| Silverman Peter B. | COO & GC |
Jun 27 '24 |
Option Exercise |
17.94 |
10,000 |
179,400 |
10,000 |
| Silverman Peter B. | COO & GC |
Jun 27 '24 |
Sale |
60.00 |
10,000 |
600,000 |
0 |
| Silverman Peter B. | COO & GC |
Jun 17 '24 |
Option Exercise |
24.36 |
62,000 |
1,510,280 |
62,000 |
| Silverman Peter B. | COO & GC |
Jun 17 '24 |
Sale |
56.52 |
62,000 |
3,504,178 |
0 |
| Shuman Harry | VP Controller, PAO |
Jun 12 '24 |
Sale |
57.84 |
7,300 |
422,232 |
7,002 |
| Shuman Harry | VP Controller, PAO |
Jun 10 '24 |
Sale |
53.22 |
1,000 |
53,224 |
7,002 |
| Shuman Harry | VP Controller, PAO |
Jun 04 '24 |
Sale |
52.89 |
6,000 |
317,354 |
7,002 |
| Shuman Harry | VP Controller, PAO |
Dec 19 '23 |
Sale |
26.68 |
115 |
3,068 |
7,002 |
| Silverman Peter B. | COO & GC |
Dec 15 '23 |
Sale |
25.00 |
22,386 |
559,650 |
0 |
0.42%
0.16%
자본화:
|
볼륨(24시간):